title: Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.
abstract: The human U-1285 and GLC(4) cell lines, both derived from small cell carcinoma of the lung, are present in doxorubicin-sensitive (U-1285 and GLC(4)) and doxorubicin-resistant MRP-expressing (U-1285dox and GLC(4)/ADR) variants. These sublines were examined here with respect to their susceptibilities to the toxic effects of selenite and compared to the toxic effects of selenite on the promyelocytic leukemia cell line HL-60 and its doxorubicin-resistant P-glycoprotein expressing variant. The drug-resistant U-1285dox and GLC(4)/ADR sublines proved to be 3- and 4-fold, respectively, more sensitive to the cytotoxicity of selenite than the drug-sensitive U-1285 and GLC(4) sublines, whereas no difference was observed between the HL-60 sublines. The presence of doxorubicin at a concentration equal to the IC(10) did not significantly potentiate the toxic effects of selenite. The presence of selenite did not significantly affect the expression of the multi-drug resistant proteins (MRP1, LRP and topoisomerase IIalpha) in the drug-resistant cells. The activities of thioredoxin reductase (TrxR) were higher (50 and 25%, respectively) in the drug resistant cell sublines U-1285dox and GLC(4)/ADR compared to the drug-sensitive parental lines. The activity of glutathione reductase (GR) was essentially the same in the drug-sensitive and -resistant cell lines. Exposure to selenite resulted in a 4-fold increase in both TrxR and GR activities in U-1285 cells, an effect, which was less pronounced in the presence of doxorubicin. Under similar conditions the increase in the TrxR activity in the resistant U-1285dox cell line, was only 30% and the activity of GR was unaltered. Different responses in the activity of the key enzymes in selenium metabolism are one possible mechanism explaining the differential cytotoxicity of selenium in these cells.
authors.affiliation: Division of Pathology, Department of Microbiology, Pathology and Immunology, Karolinska Institutet, Huddinge University Hospital, SE-141 86 Stockholm, Sweden.
authors.forename: Linda
authors.initials: L
authors.lastname: Björkhem-Bergman
authors.forename: Kerstin
authors.initials: K
authors.lastname: Jönsson
authors.forename: Lennart C
authors.initials: LC
authors.lastname: Eriksson
authors.forename: Jerker M
authors.initials: JM
authors.lastname: Olsson
authors.forename: Sören
authors.initials: S
authors.lastname: Lehmann
authors.forename: Christer
authors.initials: C
authors.lastname: Paul
authors.forename: Mikael
authors.initials: M
authors.lastname: Björnstedt
mesh_terms: D015153:Blotting, Western; D002455:Cell Division / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000502:physiology*; D005980:Glutathione Reductase / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D018038:Sodium Selenite / Q000494:pharmacology*; D013880:Thioredoxin-Disulfide Reductase / Q000187:drug effects / Q000378:metabolism*; D014407:Tumor Cells, Cultured
chemical_list: D005980:Glutathione Reductase; D013880:Thioredoxin-Disulfide Reductase; D018038:Sodium Selenite